P2, N=68, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: May 2028 --> May 2029 | Trial primary completion date: May 2026 --> Apr 2027

19 hours ago

Trial completion date • Trial primary completion date

CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)

CD22 positive

clonoSEQ

Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)

P3, N=875, Recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | Not yet recruiting --> Recruiting | N=328 --> 875

1 day ago

Enrollment open • Enrollment change • Trial initiation date

NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)

NPM1 mutation

cytarabine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)

Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia (clinicaltrials.gov)

P2, N=204, Recruiting, Chinese PLA General Hospital

2 days ago

New P2 trial

Venclexta (venetoclax) • cytarabine • azacitidine

CD28-Targeted Enzyme-Responsive Conformation-Switching Peptide Self-Assembly for Selective T-Cell Acute Lymphoblastic Leukemia (T-ALL) Therapy. (PubMed, Adv Sci (Weinh))

In Jurkat xenograft models, SAp-CD28 demonstrated potent antitumor activity, and its combination with cytarabine resulted in near-complete tumor suppression, highlighting its potential for T-ALL treatment. This work introduces a CD28-targeted, enzyme-activated nanotherapeutic strategy that synergizes biochemical and mechanical mechanisms to selectively eliminate T-ALL cells. This multi-mechanistic tumor-killing strategy can also be extended to inspire therapeutic approaches for other diseases.

5 days ago

Journal

CD28 (CD28 Molecule)

cytarabine

DECISIVO: Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients (clinicaltrials.gov)

P2, N=50, Not yet recruiting, PETHEMA Foundation

5 days ago

New P2 trial

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

IDH1 R132

cytarabine • Tibsovo (ivosidenib) • Inqovi (decitabine/cedazuridine) • hydroxyurea

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=200, Recruiting, Chinese PLA General Hospital | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2029

6 days ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • fludarabine IV • aclarubicin

Discovery of METTL3 inhibitor C191-0266 as a leukemia therapeutic through targeted modulation of protective autophagy. (PubMed, Leuk Res)

To develop novel anti-leukemia therapies, a CNN model identified C191-0266 targeting METTL3, which exhibited potent anti-leukemia activity. It inhibited the proliferation of OCI-AML3, MOLM-13, and THP-1 cell lines with IC50 values of 16.91 μM, 19.01 μM, and 24.99 μM respectively, showed strong METTL3 binding (KD = 7.28 μM) and enzymatic inhibition (IC50 = 7.639 μM), enhanced Ara-C's cytotoxicity by suppressing Ara-C-induced protective autophagy, maintained stable binding to METTL3, regulated the NF-κB pathway to inhibit TNF-α overexpression in Ara-C-resistant cell lines, and had favorable pharmacokinetics and safety profiles via ADME assessments, thus holding promise as an anti-leukemia drug candidate.

6 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • METTL3 (Methyltransferase Like 3)

cytarabine

Targeting LAPTM5 enhances AML sensitivity to cytarabine through autophagy inhibition. (PubMed, Cell Death Dis)

This facilitates autophagolysosome formation and enhances autophagic flux to reduce AraC-induced apoptosis, resulting in drug resistance. Targeting LAPTM5 represents a promising strategy to overcome this autophagy-mediated resistance.

7 days ago

Journal

LAMP1 (Lysosomal Associated Membrane Protein 1) • LAMP2 (Lysosomal Associated Membrane Protein 2) • LAPTM5 (Lysosomal Protein Transmembrane 5)

cytarabine

AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov)

P3, N=9350, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2028 --> Mar 2026

7 days ago

Trial completion date

cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

QuANTUM-WILD: Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (clinicaltrials.gov)

P3, N=700, Recruiting, Daiichi Sankyo | N=283 --> 700

7 days ago

Enrollment change

cytarabine • Vanflyta (quizartinib) • daunorubicin • idarubicin hydrochloride